89 related articles for article (PubMed ID: 22117782)
1. Determination of the biological variation of S100β and lactate dehydrogenase in disease-free patients with malignant melanoma.
Trapé J; Montesinos J; Franquesa J; Sala M; Fígols C; Miguel A; Domenech M
Clin Chem Lab Med; 2011 Nov; 50(5):927-9. PubMed ID: 22117782
[TBL] [Abstract][Full Text] [Related]
2. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
3. Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100beta or melanoma inhibitory activity (MIA)?
Deichmann M; Benner A; Kuner N; Wacker J; Waldmann V; Näher H
Melanoma Res; 2001 Jun; 11(3):291-6. PubMed ID: 11468518
[TBL] [Abstract][Full Text] [Related]
4. Serum S100beta protein as a marker of disease activity in patients with malignant melanoma.
Mohammed MQ; Abraha HD; Sherwood RA; MacRae K; Retsas S
Med Oncol; 2001; 18(2):109-20. PubMed ID: 11778756
[TBL] [Abstract][Full Text] [Related]
5. Determination of biological variation of α-fetoprotein and choriogonadotropin (β chain) in disease-free patients with testicular cancer.
Trapé J; Franquesa J; Sala M; Domenech M; Montesinos J; Catot S; Buxó J; Casado E; Fígols C; Harillo S; Galobart J; Bella M
Clin Chem Lab Med; 2010 Dec; 48(12):1799-801. PubMed ID: 20828364
[TBL] [Abstract][Full Text] [Related]
6. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
Ugurel S; Bell N; Sucker A; Zimpfer A; Rittgen W; Schadendorf D
Int J Cancer; 2005 Dec; 117(5):825-30. PubMed ID: 15957165
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
8. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
[TBL] [Abstract][Full Text] [Related]
9. MIA, S100 and LDH as important predictors of overall survival of patients with stage IIb and IIc melanoma.
Nikolin B; Djan I; Trifunovic J; Dugandzija T; Novkovic D; Djan V; Vucinic N
J BUON; 2016; 21(3):691-7. PubMed ID: 27569092
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
11. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase.
Krähn G; Kaskel P; Sander S; Waizenhöfer PJ; Wortmann S; Leiter U; Peter RU
Anticancer Res; 2001; 21(2B):1311-6. PubMed ID: 11396205
[TBL] [Abstract][Full Text] [Related]
12. S100beta protein and amniotic fluid.
Benn P
Clin Chim Acta; 2003 Sep; 335(1-2):169. PubMed ID: 12927700
[No Abstract] [Full Text] [Related]
13. Do changes in S100beta protein correlate with serum magnesium concentrations in patients undergoing extracorporeal circulation?
Dabrowski W
Magnes Res; 2007 Sep; 20(3):168-76. PubMed ID: 17972459
[TBL] [Abstract][Full Text] [Related]
14. S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma.
Schmidt H; Sorensen BS; Nexo E; von der Maase H
Melanoma Res; 2004 Jun; 14(3):211-5. PubMed ID: 15179191
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of the temporal course of S100beta protein in post-acute severe brain injury: A prospective and observational study.
Murillo-Cabezas F; Muñoz-Sánchez MA; Rincón-Ferrari MD; Martín-Rodríguez JF; Amaya-Villar R; García-Gómez S; León-Carrión J
Brain Inj; 2010; 24(4):609-19. PubMed ID: 20235763
[TBL] [Abstract][Full Text] [Related]
16. S100beta as a predictor of brain metastases: brain versus cerebrovascular damage.
Vogelbaum MA; Masaryk T; Mazzone P; Mekhail T; Fazio V; McCartney S; Marchi N; Kanner A; Janigro D
Cancer; 2005 Aug; 104(4):817-24. PubMed ID: 15971200
[TBL] [Abstract][Full Text] [Related]
17. Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma.
Alber B; Hein R; Garbe C; Caroli U; Luppa PB
Clin Chem Lab Med; 2005; 43(5):557-63. PubMed ID: 15899680
[TBL] [Abstract][Full Text] [Related]
18. Early postoperative serum S100 beta levels predict ongoing brain damage after meningioma surgery: a prospective observational study.
Einav S; Shoshan Y; Ovadia H; Matot I; Hersch M; Itshayek E
Crit Care; 2006; 10(5):R141. PubMed ID: 17020600
[TBL] [Abstract][Full Text] [Related]
19. Peripheral detection of S100beta during cardiothoracic surgery: what are we really measuring?
Fazio V; Bhudia SK; Marchi N; Aumayr B; Janigro D
Ann Thorac Surg; 2004 Jul; 78(1):46-52; discussion 52-3. PubMed ID: 15223400
[TBL] [Abstract][Full Text] [Related]
20. [Serum S100β protein reference values in a paediatric population].
Arroyo Hernández M; Rodríguez Suárez J; Álvarez Menéndez F
An Pediatr (Barc); 2016 May; 84(5):254-9. PubMed ID: 26589475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
